Safety Study of Abatacept to Treat Rheumatoid Arthritis (A)

Efficacy, Pharmacokinetics, Safety, and Immunogenicity Study of Abatacept Administered Subcutaneously to Treat Rheumatoid Arthritis in Japanese Patients

NCT01001832 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF Therapy

NCT00162201 ·Status: COMPLETED ·Phase: PHASE1

Phase IIIB Subcutaneous Abatacept Monotherapy Study

NCT00547521 ·Status: COMPLETED ·Phase: PHASE3

Post-marketing Study Assessing the Long-Term Safety of Abatacept

NCT02169544 ·Status: COMPLETED

A Phase III Study of Abatacept in Japanese Subjects With Rheumatoid Arthritis

NCT00484289 ·Status: COMPLETED ·Phase: PHASE3

Safety Study of Abatacept to Treat Rheumatoid Arthritis

NCT01247766 ·Status: COMPLETED

A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate

NCT00048568 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate Biomarkers to Predict Efficacy of Abatacept in Rheumatoid Arthritis

NCT03882008 ·Status: COMPLETED ·Phase: PHASE4

Abatacept Versus Adalimumab Head-to-Head

NCT00929864 ·Status: COMPLETED ·Phase: PHASE3

Remission and Joint Damage Progression in Early Rheumatoid Arthritis

NCT00122382 ·Status: COMPLETED ·Phase: PHASE3

Safety Study of Abatacept in Sweden

NCT01094795 ·Status: COMPLETED

A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

NCT03086343 ·Status: COMPLETED ·Phase: PHASE3

A Phase III Study of Abatacept in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

NCT00409838 ·Status: COMPLETED ·Phase: PHASE3

Effects of Abatacept in Patients With Early Rheumatoid Arthritis

NCT02504268 ·Status: COMPLETED ·Phase: PHASE3

Pharmacokinetics, Safety and Tolerability Study of Single Dose of Abatacept 125mg Administered Subcutaneously

NCT02805010 ·Status: UNKNOWN ·Phase: PHASE1

Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis

NCT02557100 ·Status: COMPLETED ·Phase: PHASE4

Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients

NCT01351480 ·Status: COMPLETED ·Phase: PHASE3

Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)

NCT00254293 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Phase IIIB Subcutaneous Missed Dose Study

NCT00533897 ·Status: COMPLETED ·Phase: PHASE3

Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis

NCT00095147 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-122 in Subjects With Rheumatoid Arthritis

NCT01853033 ·Status: COMPLETED ·Phase: PHASE1

Methotrexate-Inadequate Response Study

NCT00559585 ·Status: COMPLETED ·Phase: PHASE3

Abatacept With Methotrexate- Phase IIB

NCT00162266 ·Status: COMPLETED ·Phase: PHASE2

A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX)

NCT02349451 ·Status: COMPLETED ·Phase: PHASE2

Does Abatacept Induce Regulatory B Cells in Patients With Rheumatoid Arthritis

NCT02885818 ·Status: COMPLETED